Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.59 |
| ▸ | CTSS | P25774 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28681860 | 1.00 | CTSK (0.59) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL4751952 | 1.00 | CTSK (0.59) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL17268414 | 0.86 | CTSK (0.55) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL17268444 | 0.86 | CTSK (0.55) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL4958751 | 0.85 | CTSK (0.62) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL10727467 | 0.85 | CTSK (0.62) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL10722482 | 0.85 | CTSK (0.62) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL20504152 | 0.85 | CTSK (0.54) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL2494959 | 0.85 | CTSK (0.54) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL14389814 | 0.84 | CTSK (0.56) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535614-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210238174-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-08-05 | — | — | US | disclosed |
| US-11001583-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-20200339566-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. | 2020-10-29 | — | — | US | disclosed |
| US-10807980-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200172535-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-20200079767-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2020-03-12 | — | — | US | disclosed |
| EP-3207043-B3 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10399976-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3527569-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA FOR USE IN TREATING DRYE EYE | Vitae Pharmaceuticals, LLC (US) | 2019-08-21 | — | — | EP | disclosed |
| CN-102046618-A | Hydroxyquinoxalinecarboxamide derivative | DAIICHI SANKYO CO LTD | 2011-05-04 | — | — | CN | disclosed |
| US-7678765-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2010-03-16 | — | — | US | disclosed |
| WO-2008132162-A1 | 3- (SULPHONYLAMINO) -PHENYL-2 -HYDROXY-ETHYLAMINO DERIVATIVES USEFUL AS BETA-AGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1294747-B1 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR SA (ES) | 2008-04-30 | — | — | EP | disclosed |
| US-7348310-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2008-03-25 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
| US-20040097413-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2004-05-20 | — | — | US | disclosed |
| EP-1294747-A2 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR, S.A. (ES) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002002596-A2 | SYNTHETIC METHODS FOR APLIDINE AND NEW ANTITUMORAL DERIVATIVES, METHODS OF MAKING AND USING THEM | PHARMA MAR, S.A. (ES) | 2002-01-10 | — | — | WO | disclosed |
| US-4816598-A | 4-Amino-butanoic acid derivatives | SANOFI (FR) | 1989-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001583-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | CTSK 4102/4885CTSS 4720/4885CA2 1302/4885 |
| US-20040097413-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, PML, APLNR | CTSK 3011/4885CTSS 3199/4885CA2 4520/4885 |
| US-20200172535-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | CTSK 4102/4885CTSS 4720/4885CA2 1302/4885 |
| US-10399976-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | CTSK 4223/4885CTSS 4754/4885CA2 1037/4885 |
| US-20210238174-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | CTSK 4102/4885CTSS 4720/4885CA2 1302/4885 |
| US-10807980-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | CTSK 4102/4885CTSS 4720/4885CA2 1302/4885 |
| US-20200079767-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | CTSK 4102/4885CTSS 4720/4885CA2 1302/4885 |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, APLNR, PAICS | CTSK 3079/4885CTSS 3273/4885CA2 4013/4885 |
| US-20200339566-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | CTSK 4102/4885CTSS 4720/4885CA2 1302/4885 |
| US-11535614-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | CTSK 4102/4885CTSS 4720/4885CA2 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.